IVA · Inventiva S.A.

Current Thesis

Inventiva’s lanifibranor case still depends on the Q4 2026 NATiV3 results, but its pre-readout price thesis has already failed the published $4.40 weekly-close condition. The week-ending 2026-09-18 reference close was $3.78, below the June offering level that the 2026-09-05 dossier identified as its invalidation threshold. The clinical hypothesis remains unresolved; the price condition does not.

For that pre-readout price leg, the narrative is dead — an analytical classification dated by the 2026-09-18 close below the published threshold. This does not establish that lanifibranor failed clinically. Inventiva’s 2026-09-02 announcement retained Q4 2026 topline guidance after the final patient visit; results showing efficacy and acceptable safety remain the evidence needed to establish the clinical case. Inventiva announcement, 2026-09-02.

Bullish and bearish views on Inventiva S.A.

The model's bull view on Inventiva S.A. (IVA), in brief: Trial treatment has finished. Inventiva’s 2026-09-02 release reported completion of the final 72-week visit, with 1,009 patients in the main cohort. That is evidence of trial progress, not evidence that the efficacy endpoints succeeded. Company release. Reported liquidity… The bear view: The published price condition fired. The 2026-09-18 close of $3.78 was below the $4.40 offering price announced on 2026-06-02 and adopted as the prior dossier’s weekly invalidation threshold. The earlier $4.78 close on 2026-09-04 therefore no longer supports the description of… Both cases follow in full.

Bull Case

• Trial treatment has finished. Inventiva’s 2026-09-02 release reported completion of the final 72-week visit, with 1,009 patients in the main cohort. That is evidence of trial progress, not evidence that the efficacy endpoints succeeded. Company release.
• Reported liquidity extends beyond guidance. The 2026-07-29 preliminary financial release reported €166.1 million of cash and cash equivalents and €67.8 million of short-term deposits at 2026-06-30. Management projected funding through the end of Q2 2027, beyond its stated clinical-results window; that projection remains conditional on spending and timing.

Bear Case

• The published price condition fired. The 2026-09-18 close of $3.78 was below the $4.40 offering price announced on 2026-06-02 and adopted as the prior dossier’s weekly invalidation threshold. The earlier $4.78 close on 2026-09-04 therefore no longer supports the description of shares holding above that shelf.
• Longer runway remains conditional. The 2026-07-29 release stated that current cash was insufficient for the next 12 months of planned operations. Neither conditional funding nor projected runway establishes that additional proceeds have arrived.
• Research spending remained substantial. The 2026-07-29 release reported first-half 2026 research and development expenses of €50.1 million, versus €44.9 million in first-half 2025, alongside zero first-half 2026 revenue. Those reported figures leave clinical execution and financing central to the case.

Setup & Price Structure

Measured at 2026-09-18, the adjusted daily reference close was $3.78, the three-month price change was positive 7.7%, and the shares were 47.1% below the supplied 52-week high of $7.15. The 14-period relative strength index (RSI) was 15.6. That momentum reading does not establish a reversal; no supplied moving-average or volume series establishes a new base.

The $4.40 June offering level is now a failed reference shelf. The interpretation follows the observed close below it, rather than a prediction about the next daily move. The supplied price observations are insufficient to estimate the probability of a rebound or attribute the decline to a particular group of shareholders.

Positioning evidence is limited. The dated 2026-09-05 S&P Global analyst snapshot, reproduced in the prior dossier from Stock Analysis, showed 13 analysts, all with positive recommendations, and a mean price target of $14.88. That measures published analyst opinion at that date; it does not measure current ownership, short interest or retail participation. No refreshed analyst panel or retail-flow series establishes whether that agreement persisted through 2026-09-18.

Catalyst Calendar (next 30 days)

• 2026-09-28 — First-half financial results. This is the next scheduled opportunity to assess updated liquidity and clinical timing, according to Inventiva’s 2026-09-02 calendar. An explicit postponement would weaken the remaining clinical timetable; silence alone would not prove a postponement. Company calendar.
• 2026-09-30 — Scheduled investor discussions. Inventiva’s 2026-09-02 release lists the Stifel Virtual Cardiometabolic Forum and Jefferies Healthcare C-Suite series. These are communication events, without an announced clinical-data release attached. Company calendar.

What Would Change Our Mind

Loss of the June offering shelf has already broken the prior price thesis: a weekly close below $4.40 was the published condition, and the week-ending 2026-09-18 close was $3.78. Replacing that threshold with a lower historical price would erase the original test.

A subsequent weekly close above $4.40 would establish a reclaim of the failed shelf, although it would not reverse the recorded invalidation. On the company side, the 2026-09-28 release can supply updated funding evidence. Actual NATiV3 results must resolve the clinical hypothesis; failure on the fibrosis endpoint or a disclosed safety finding that prevents development would break it.

Correlation Notes

This remains a single-name clinical catalyst case. The 2026-09-02 trial milestone is company-specific, and the supplied 2026-09-18 price snapshot contains no matched biotechnology-index or peer return series. It cannot establish whether the decline reflects sector movement, company-specific repricing or both. No numerical correlation or group-driven recovery claim is supported by this evidence.